Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)

Nutr Metab Cardiovasc Dis. 2020 Aug 28;30(9):1427-1441. doi: 10.1016/j.numecd.2020.05.004. Epub 2020 May 21.

Abstract

Chronic metabolic alterations such as post-transplant diabetes mellitus (PTDM), dyslipidaemias and overweight/obesity significantly impact on kidney transplant (KT) outcomes. This joint position statement is based on the evidence on the management of metabolic alterations in KT recipients (KTRs) published after the release of the 2009 KDIGO clinical practice guideline for the care of KTRs. Members of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID) selected to represent professionals involved in the management of KTRs undertook a systematic review of the published evidence for the management of PTDM, dyslipidaemias and obesity in this setting. The aim of this work is to provide an updated review of the evidence on the prevention, diagnosis and treatment of metabolic alterations in KTRs, in order to support physicians, patients and the Healthcare System in the decision-making process when choosing among the various available options.

Keywords: Dyslipidaemia; Kidney transplant; Obesity; Overweight; Post-transplant diabetes mellitus.

Publication types

  • Practice Guideline
  • Systematic Review

MeSH terms

  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Clinical Decision-Making
  • Consensus
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / therapy*
  • Drug Substitution
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / epidemiology
  • Dyslipidemias / therapy*
  • Energy Metabolism / drug effects*
  • Evidence-Based Medicine
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Kidney Transplantation / adverse effects*
  • Lipids / blood
  • Obesity / blood
  • Obesity / diagnosis
  • Obesity / epidemiology
  • Obesity / therapy*
  • Patient Selection
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior*

Substances

  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Immunosuppressive Agents
  • Lipids